Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan R Shuldiner

Showing results (21-30 of 405) with videos related to

Pageof 41
Sort By:
Evidence-Based Medicine|June 28, 2011
Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrelAndrea H Ramirez, Jessica T Delaney, Alan R Shuldiner
JACC. Cardiovascular Interventions|November 21, 2009
The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patientPaul A Gurbel, Udaya S Tantry, Alan R Shuldiner
Pharmacogenetics and Genomics|October 13, 2010
Platelet aggregation pathwayKatrin Sangkuhl, Alan R Shuldiner, Teri E Klein, et al.
Physiological Genomics|September 5, 2002
Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effectsEdward P Weiss, Michael D Brown, Alan R Shuldiner, et al.
Journal of the American College of Cardiology|May 18, 2010
Genotyping: one piece of the puzzle to personalize antiplatelet therapyPaul A Gurbel, Udaya S Tantry, Alan R Shuldiner, et al.
Current Diabetes Reports|March 20, 2003
Genetics of insulin resistanceMaria M Mercado, John C McLenithan, Kristi D Silver, et al.
Metabolism: Clinical and Experimental|May 31, 2002
No effect of the Trp64Arg beta(3)-adrenoceptor gene variant on weight loss, body composition, or energy expenditure in obese, caucasian postmenopausal womenEric S Rawson, Amy Nolan, Kristi Silver, et al.
Diabetes|July 26, 2014
Metformin pharmacogenomics: current status and future directionsAaron C Pawlyk, Kathleen M Giacomini, Catherine McKeon, et al.
Diabetes|June 28, 2003
A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima IndiansYunhua Li Muller, Clifton Bogardus, Brock A Beamer, et al.
Journal of Clinical Epigenetics|January 30, 2018
Epigenetic Signature of Impaired Fasting Glucose in the Old Order AmishMay E Montasser, Yu-Ching Cheng, Keith Tanner, et al.
Pageof 41

Showing results (21-30 of 405) with videos related to

Sort By:
Pageof 41
Evidence-Based Medicine|June 28, 2011
Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrelAndrea H Ramirez, Jessica T Delaney, Alan R Shuldiner
JACC. Cardiovascular Interventions|November 21, 2009
The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patientPaul A Gurbel, Udaya S Tantry, Alan R Shuldiner
Pharmacogenetics and Genomics|October 13, 2010
Platelet aggregation pathwayKatrin Sangkuhl, Alan R Shuldiner, Teri E Klein, et al.
Physiological Genomics|September 5, 2002
Fatty acid binding protein-2 gene variants and insulin resistance: gene and gene-environment interaction effectsEdward P Weiss, Michael D Brown, Alan R Shuldiner, et al.
Journal of the American College of Cardiology|May 18, 2010
Genotyping: one piece of the puzzle to personalize antiplatelet therapyPaul A Gurbel, Udaya S Tantry, Alan R Shuldiner, et al.
Current Diabetes Reports|March 20, 2003
Genetics of insulin resistanceMaria M Mercado, John C McLenithan, Kristi D Silver, et al.
Metabolism: Clinical and Experimental|May 31, 2002
No effect of the Trp64Arg beta(3)-adrenoceptor gene variant on weight loss, body composition, or energy expenditure in obese, caucasian postmenopausal womenEric S Rawson, Amy Nolan, Kristi Silver, et al.
Diabetes|July 26, 2014
Metformin pharmacogenomics: current status and future directionsAaron C Pawlyk, Kathleen M Giacomini, Catherine McKeon, et al.
Diabetes|June 28, 2003
A functional variant in the peroxisome proliferator-activated receptor gamma2 promoter is associated with predictors of obesity and type 2 diabetes in Pima IndiansYunhua Li Muller, Clifton Bogardus, Brock A Beamer, et al.
Journal of Clinical Epigenetics|January 30, 2018
Epigenetic Signature of Impaired Fasting Glucose in the Old Order AmishMay E Montasser, Yu-Ching Cheng, Keith Tanner, et al.
Pageof 41